Holen Sie sich die Stockscreener-App
4.655
4.43%
0.195
Verastem Inc Aktie (VSTM) Neueste Nachrichten
RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating - marketscreener.com
Here’s What RBC Capital Has to Say About Verastem (VSTM) - Insider Monkey
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
VSTM Maintained by BTIG -- Price Target Unchanged at $18.00 - GuruFocus
Verastem Is Maintained at Buy by BTIG - Moomoo
Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Insider Monkey
5 Best Stocks Under $10 Offering More Than 50% Upside - Insider Monkey
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem, Inc. Actuals & Estimates (SWB:2VSA) - TradingView
Verastem, Inc. Stock Hits New 52-Week Low at $3.43 - MarketsMojo
Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM) - TradingView
Price to earnings forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
VSTM Forecast — Price Target — Prediction for 2027 - TradingView
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Price to book forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) insider sale notice: 21,492 shares reported for resale - Stock Titan
Verastem, Inc. Actuals & Estimates (GETTEX:2VSA) - TradingView
Enterprise value to revenue forward of Verastem, Inc. – GETTEX:2VSA - TradingView
2VSA Forecast — Price Target — Prediction for 2027 - TradingView
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer? - Insider Monkey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Price to sales forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Price to book forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Verastem CEO Dan Paterson sells $87,240 in shares By Investing.com - Investing.com India
Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares - GuruFocus
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18.00 - GuruFocus
Verastem CFO Daniel Calkins sells $17,089 in company stock By Investing.com - Investing.com Australia
Form 4 Verastem Inc For: 24 June By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares - Investing.com UK
Verastem CFO Daniel Calkins sells $17,089 in company stock - Investing.com
Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding - Stock Titan
Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes - Stock Titan
VSTM Q1 2026 Earnings: EPS Beats Estimates by 2.19% as Pre-Revenue Biotech Advances Pipeline - dars.gov.et
VSTM Reiterates by BTIG -- Price Target Maintained at $18.00 - GuruFocus
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential - Investing.com
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $8 to $18 - Moomoo
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated CancersSlideshow (NASDAQ:VSTM) 2026-06-24 - Seeking Alpha
H.C. Wainwright reiterates Verastem stock rating on drug trial data By Investing.com - Investing.com UK
VSTM Maintains Rating by Jefferies -- Price Target Lowered to $8 - GuruFocus
Verastem (VSTM) Reports Promising Outcomes from Phase 1/2 Trial of VS-7375 - GuruFocus
Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375 - Moomoo
Verastem Advances VS-7375 with Promising Early Trial Data - TipRanks
Verastem stock falls despite early cancer drug trial data By Investing.com - Investing.com South Africa
1.38%
3.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):